Jiangsu, China

Zhipeng Su

This inventor holds 1 USPTO granted patent and 7 published patent applications, plus 1 CIPO patent. Top assignee: Regenecore Biotech Co., Ltd. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhipeng Su. Retrieved from https://idiyas.com/inventor/zhipeng-su

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zhipeng Su: Innovator in Biotech

Introduction

Zhipeng Su is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic solutions. His work focuses on advancing medical treatments through cutting-edge research and development.

Latest Patents

Zhipeng Su holds a patent for a "Humanized Anti-IL-4Ra Single Domain Antibody and Application Thereof." This invention represents a breakthrough in targeted therapies, offering potential benefits for patients suffering from various conditions related to IL-4Ra.

Career Highlights

Zhipeng Su is currently employed at Regenecore Biotech Co., Ltd. His role at the company allows him to leverage his expertise in biotechnology to drive forward innovative projects. His dedication to research and development has positioned him as a key figure in his field.

Collaborations

Zhipeng has collaborated with notable colleagues, including Yun Zhang and Jinguo Meng. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in biotechnology.

Conclusion

Zhipeng Su's contributions to biotechnology through his patent and collaborative efforts highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…